RENE.L Regulatory News (RENE)

ReNeuron Group plc

("ReNeuron" or "the Company")

Block Listing Application

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that an application has been made to the London Stock Exchange plc for a block admission of 902,825 ordinary shares of 1p each in the capital of the Company ("New Ordinary Shares") to be admitted to trading on AIM ("Replacement Block Admission"). This application is to replace the Company's previous block listing scheme and is being made solely as a result of its recent 1 for 100 share capital consolidation, announced as approved on 23 January 2018 (the "Reorganisation").

This new ReNeuron Share Option Schemes block listing scheme (the "Scheme") will allow New Ordinary Shares to be issued and allotted from time to time pursuant to the exercise of options under the Company's share option schemes. The New Ordinary Shares, when issued, shall rank pari passu with the Company's existing issued ordinary shares. It is expected that the block listing will become effective on 21 February 2018.

The Company's original block listing scheme of 2,000,000 ordinary shares was admitted to AIM on 13 May 2010, with a further application for a block admission of 97,015,627 ordinary shares to be admitted to trading on AIM made on 28 September 2015. Immediately prior to the Reorganisation the Company had 90,282,511 of unallotted shares under this original scheme. Following the Reorganisation, and this subsequent Replacement Block Admission of 902,825 New Ordinary Shares, there will be 902,825 unallotted shares under the Scheme.

ENQUIRIES:

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.